美托洛尔、曲美他嗪治疗冠心病心力衰竭分析

Analysis of Metoprolol and Trimetazidine in the Treatment of Coronary Heart Disease and Deart Failure

目的分析美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效。方法选取2017 年3 月—2018 年7 月收治的患者92 例为研究对象,随机分为对照组46 例,进行常规治疗,采用观察组46 例,进行美托洛尔、曲美他嗪治疗,对比各种治疗方式的效果。结果观察组患者左室射血分数(LVEF)、左心室收缩末期内径(LVESD)等评分均有显著改善,差异有统计学意义(P < 0.05);观察组患者心率、血压和对照组比更优,且差异有统计学意义(P < 0.05);观察组患者总有效率要显著高于对照组,差异有统计学意义(P < 0.05)。结论为冠心病心力衰竭患者采用美托洛尔联合曲美他嗪治疗时疗效显著,可改善患者心功能,有应用价值。

Objective To analyze the clinical efficacy of metoprolol combined with trimetazidine in the treatment of coronary heart disease with heart failure. Methods A total of 92 patients admitted from March 2017 to July 2018 were enrolled in the study. They were randomly divided into the control group (n = 46) and routinely treated. 46 patients in the observation group were treated with metoprolol and trimetazidine. Compare the effects of various treatments. Results In the observation group, the scores of LVEF (left ventricular ejection fraction) and LVESD (left ventricular endsystolic diameter) were significantly improved, and the difference was statistically significant (P < 0.05). The heart rate, blood pressure and control group of the observation group were more. The difference was statistically significant (P < 0.05). The total effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P < 0.05). Conclusion The efficacy of metoprolol combined with trimetazidine in the treatment of patients with coronary heart disease and heart failure is significant, which can improve the heart function of patients and has application value.